Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cavosonstat (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms SNO-6
- Sponsors Nivalis Therapeutics
- 01 May 2017 According to a Nivalis Therapeutics media release, following disappointing results of two phase II trials (SNO-6 and SNO-7) of cavosonstat in cystic fibrosis, the company has determined to not pursue the development of this drug in cystic fibrosis and to wind down its research and development activities.
- 28 Nov 2016 Status changed from active, no longer recruiting to completed, as per a Nivalis Therapeutics media release.
- 28 Nov 2016 Top-line results published in a Nivalis Therapeutics media release.